CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Published:2013-03-20 Issue:177 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Brentjens Renier J.¹²³,Davila Marco L.¹,Riviere Isabelle¹²³⁴,Park Jae¹,Wang Xiuyan³⁴,Cowell Lindsay G.⁵,Bartido Shirley⁴,Stefanski Jolanta⁴,Taylor Clare⁴,Olszewska Malgorzata⁴,Borquez-Ojeda Oriana⁴,Qu Jinrong⁴,Wasielewska Teresa⁴,He Qing⁴,Bernal Yvette¹,Rijo Ivelise V.⁶,Hedvat Cyrus⁶,Kobos Rachel⁷,Curran Kevin⁷,Steinherz Peter⁷,Jurcic Joseph¹,Rosenblat Todd¹,Maslak Peter¹,Frattini Mark¹,Sadelain Michel¹²³

Affiliation:

1. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

2. Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

3. Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

4. Cell Therapy and Cell Engineering Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

5. Department of Clinical Sciences, UT Southwestern, Dallas, TX 75390, USA.

6. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

7. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Abstract

Five adults with chemotherapy-refractory B-ALL were induced into molecular remissions after treatment with CD19 CAR-targeted T cells.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference25 articles.

1. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

3. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

4. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

5. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B–lineage leukemia effect

Cited by 1702 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output;Molecular Therapy - Methods & Clinical Development;2024-03

2. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma;Transplantation and Cellular Therapy;2024-02

3. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells;Journal of Immunological Methods;2024-02

4. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer;BMC Cancer;2024-01-23

5. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells;Nature Communications;2024-01-19